# NOVAVAX INC

NOVAVAX INC is a public company listed on Nasdaq as NVAX, headquartered in Gaithersburg, MD, United States.

## Company overview

- **Legal name:** NOVAVAX INC
- **Classification:** Public company
- **Industry (SIC):** 2836 — Biological Products, (No Diagnostic Substances)
- **Headquarters:** Gaithersburg, MD, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **Ticker:** Nasdaq: NVAX
- **SEC CIK:** 0001000694

## About

NOVAVAX INC is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001000694, and its reported industry is Biological Products, (No Diagnostic Substances). In 10-K filed on 2026-02-26, it reported annual revenue of USD 1,123,479,000; net income of USD 440,302,000; total assets of USD 1,176,512,000 for the fiscal period ended 2025-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2025 (period ended 2025-12-31)

- **Revenue:** $1.1B (USD 1,123,479,000)
- **Net income:** $440.3M (USD 440,302,000)
- **Total assets:** $1.2B (USD 1,176,512,000)
- **Cash and equivalents:** $240.6M (USD 240,634,000)
- **Operating cash flow:** -$244.6M (USD -244,635,000)

### FY2024 (period ended 2024-12-31)

- **Revenue:** $682.2M (USD 682,162,000)
- **Net income:** -$187.5M (USD -187,499,000)
- **Total assets:** $1.6B (USD 1,560,418,000)
- **Cash and equivalents:** $530.2M (USD 530,230,000)
- **Operating cash flow:** -$87.3M (USD -87,263,000)

### FY2023 (period ended 2023-12-31)

- **Revenue:** $983.7M (USD 983,705,000)
- **Net income:** -$545.1M (USD -545,062,000)
- **Total assets:** $1.8B (USD 1,797,490,000)
- **Cash and equivalents:** $568.5M (USD 568,505,000)
- **Operating cash flow:** -$714.0M (USD -713,967,000)

### FY2022 (period ended 2022-12-31)

- **Revenue:** $2.0B (USD 1,981,872,000)
- **Net income:** -$657.9M (USD -657,939,000)
- **Total assets:** $2.3B (USD 2,258,679,000)
- **Cash and equivalents:** $1.3B (USD 1,336,883,000)
- **Operating cash flow:** -$415.9M (USD -415,937,000)

## Recent SEC filings

- Form 8-K — filed 2026-08-06 — period 2026-08-06 — 8-K
- Form 10-Q — filed 2026-08-06 — period 2026-06-30 — 10-Q
- Form 8-K — filed 2026-06-23 — period 2026-06-18 — FORM 8-K
- Form 8-K — filed 2026-05-06 — period 2026-05-06 — 8-K
- Form 10-Q — filed 2026-05-06 — period 2026-03-31 — 10-Q
- Form DEF 14A — filed 2026-04-27 — period 2026-06-18 — DEF 14A
- Form 8-K — filed 2026-02-26 — period 2026-02-26 — 8-K
- Form 10-K — filed 2026-02-26 — period 2025-12-31 — 10-K
- Form 8-K — filed 2026-01-20 — period 2026-01-15 — FORM 8-K
- Form 8-K — filed 2026-01-12 — period 2026-01-12 — FORM 8-K
- Form 8-K — filed 2025-11-06 — period 2025-11-06 — 8-K
- Form 10-Q — filed 2025-11-06 — period 2025-09-30 — 10-Q

---

Updated: 2026-10-23T05:02:54.863002+00:00

Canonical page: https://altss.com/profile/novavax-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology